Christine Brennan, Ph.D.

Christine has over 15 years in the life-science industry including business development, corporate strategy and venture investing. She is currently Partner at MRLV and on the boards of Entrada Therapeutics and Tallac Therapeutics. She was previously on the board of Alector [NASDAQ:ALEC] and an observer on the board of Translate Bio [NASDAQ:TBIO].

Prior to MRLV, she was Principal at the Novartis Venture Fund from 2013-2017 where she was on the board of Altimmune [NASDAQ:ALT] and an observer on the boards of a number of companies including ROX Medical, lnnocrin Pharmaceuticals, Viamet Pharmaceuticals and Quartet Medicine. Prior to Novartis Venture Fund, she was Chief Business Officer at Vitae Pharmaceuticals from 2010-2013. She also she held positions in business development and marketing at small and mid-size biopharmaceutical companies. Christine received her Ph.D. in neuroscience from Dartmouth Medical School and post-doctoral research in developmental neurobiology from the National Institutes of Health.